人类激肽释放酶基因6在卵巢恶性肿瘤中的表达及其机制研究

目的 研究人组织激肽释放酶基因6（KLK6）mRNA和蛋白在卵巢肿瘤组织中的表达水平,探讨其在卵巢恶性肿瘤中的作用机制.方法 应用RT-PCR和免疫组化SP法分别检测在正常的卵巢组织、卵巢的良性肿瘤、卵巢的交界性肿瘤及卵巢的恶性肿瘤组织中KLK6的mRNA表达及蛋白的表达,探讨该基因的表达与卵巢恶性肿瘤患者的临床病理特征关系.结果 本研究显示,在卵巢癌组织中,KLK6 mRNA的表达水平与正常卵巢组织相比,显著增高;卵巢癌组织中KLK6蛋白的阳性表达率为69.4%,与正常卵巢组织（13.3%）、良性卵巢肿瘤（16.6%）和交界性卵巢肿瘤（44.0%）相比,差异有统计学意义（χ2=25.843,P＜0.001）.结论 KLK6可能参与了卵巢癌的侵袭和转移.

Expression of Human Kallikrein Gene 6 in Ovarian Carcinoma and Its Clinical Significence

Objective To study the expression of human kallikrein gene 6（KLK6） in ovarian cancers,and to investi- gae the pathogenesis in tumors. Methods RT-PCR and immunohistochemistry were used to detect the mRNA and pro- tein level of KLK6 in normal ovaries,benign ovarian tumors, borderline ovarian tumors and ovarian carcinoma tissues. Correlations between KLK6 expression and clinicopathological factors were analyzed. Results The relative expression of KLK6 mRNA was significantly higher in ovarian carcinoma than the normal ovaries, benign and borderline ovarian tumor tissues. The expression of KLK6 protein was 69.4% in ovarian cancer,obviously different from that in the nor- mal ovaries （ 13.3 ）, benign（ 1 6.6 ./0 ） and borderline ovarian tumor tissues （4 4.0 /00 ） （Zz = 2 5.8 4 3, P 0.00 1 ）. The ex- pression of KLK6 protein was associated with FIGO staging, histological grading, and lymph node metastasis. Conclu- sion KLK6 may be involved in the invasion and metastasis of epithelial ovarian carcinoma.